Hill AVS - Search Results

1

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, Belij-Rammerstorfer S, Berry L, Bibi S, Bittaye M, Cathie K, Chappell H, Charlton S, Cicconi P, Clutterbuck EA, Colin-Jones R, Dold C, Emary KRW, Fedosyuk S, Fuskova M, Gbesemete D, Green C, Hallis B, Hou MM, Jenkin D, Joe CCD, Kelly EJ, Kerridge S, Lawrie AM, Lelliott A, Lwin MN, Makinson R, Marchevsky NG, Mujadidi Y, Munro APS, Pacurar M, Plested E, Rand J, Rawlinson T, Rhead S, Robinson H, Ritchie AJ, Ross-Russell AL, Saich S, Singh N, Smith CC, Snape MD, Song R, Tarrant R, Themistocleous Y, Thomas KM, Villafana TL, Warren SC, Watson MEE, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Faust SN, Pollard AJ; Oxford COVID Vaccine Trial Group. Ramasamy MN, et al. Among authors: hill avs. Lancet. 2021 Dec 19;396(10267):1979-1993. doi: 10.1016/S0140-6736(20)32466-1. Epub 2020 Nov 19. Lancet. 2021. PMID: 33220855 Free PMC article. Clinical Trial.

2

Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes.

Gilbert SC, Schneider J, Hannan CM, Hu JT, Plebanski M, Sinden R, Hill AV. Gilbert SC, et al. Vaccine. 2002 Jan 15;20(7-8):1039-45. doi: 10.1016/s0264-410x(01)00450-9. Vaccine. 2002. PMID: 11803063

3

Prime-boost strategies for malaria vaccine development.

Dunachie SJ, Hill AV. Dunachie SJ, et al. J Exp Biol. 2003 Nov;206(Pt 21):3771-9. doi: 10.1242/jeb.00642. J Exp Biol. 2003. PMID: 14506212 Review.

4

Heterologous priming-boosting immunization of cattle with Mycobacterium tuberculosis 85A induces antigen-specific T-cell responses.

Taracha EL, Bishop R, Musoke AJ, Hill AV, Gilbert SC. Taracha EL, et al. Infect Immun. 2003 Dec;71(12):6906-14. doi: 10.1128/IAI.71.12.6906-6914.2003. Infect Immun. 2003. PMID: 14638779 Free PMC article.

5

A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.

Prieur E, Gilbert SC, Schneider J, Moore AC, Sheu EG, Goonetilleke N, Robson KJ, Hill AV. Prieur E, et al. Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):290-5. doi: 10.1073/pnas.0307158101. Epub 2003 Dec 23. Proc Natl Acad Sci U S A. 2004. PMID: 14694197 Free PMC article.

6

Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus.

Anderson RJ, Hannan CM, Gilbert SC, Laidlaw SM, Sheu EG, Korten S, Sinden R, Butcher GA, Skinner MA, Hill AV. Anderson RJ, et al. J Immunol. 2004 Mar 1;172(5):3094-100. doi: 10.4049/jimmunol.172.5.3094. J Immunol. 2004. PMID: 14978115

7

Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

Moorthy VS, Imoukhuede EB, Keating S, Pinder M, Webster D, Skinner MA, Gilbert SC, Walraven G, Hill AV. Moorthy VS, et al. J Infect Dis. 2004 Jun 15;189(12):2213-9. doi: 10.1086/421118. Epub 2004 May 24. J Infect Dis. 2004. PMID: 15181568 Clinical Trial.

8

Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin.

Vordermeier HM, Rhodes SG, Dean G, Goonetilleke N, Huygen K, Hill AV, Hewinson RG, Gilbert SC. Vordermeier HM, et al. Immunology. 2004 Jul;112(3):461-70. doi: 10.1111/j.1365-2567.2004.01903.x. Immunology. 2004. PMID: 15196215 Free PMC article.

9

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.

Behboudi S, Moore A, Gilbert SC, Nicoll CL, Hill AV. Behboudi S, et al. Vaccine. 2004 Oct 22;22(31-32):4326-31. doi: 10.1016/j.vaccine.2004.04.029. Vaccine. 2004. PMID: 15474725

10

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.

McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, Fletcher HA, Hill AV. McShane H, et al. Nat Med. 2004 Nov;10(11):1240-4. doi: 10.1038/nm1128. Epub 2004 Oct 24. Nat Med. 2004. PMID: 15502839 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

459 results

Search Page